Biomea Fusion 股價、新聞與催化劑

股票表現

股價為何變動

Following the latest company update, “Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes”, BMEA closed up 16.1% at $1.59 on Aug 24, 2026. The move occurred in the trading session associated with this clinical readout update.

公司概覽

未來催化劑

• Initial 28-day weight-reduction data from the Phase 1 BMF-650 study are expected in the second quarter of 2026.
• Twenty-six-week topline data from COVALENT-211 and COVALENT-212 are expected in the fourth quarter of 2026.

近期新聞

1. 01
   2026-08-24 11:00 EST

   Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

2. 02
   2026-08-13 11:00 EST

   Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

3. 03
   2026-08-05 20:05 EST

   Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

4. 04
   2026-06-05 23:32 EST

   Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

5. 05
   2026-06-03 12:00 EST

   Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

相似股票

商業成熟度、治療領域或催化劑模式相近的同業公司。